<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635530</url>
  </required_header>
  <id_info>
    <org_study_id>T1/2012</org_study_id>
    <nct_id>NCT01635530</nct_id>
  </id_info>
  <brief_title>Study of Lyme Neuroborreliosis</brief_title>
  <official_title>Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether four weeks treatment with oral
      doxycycline is as equally effective as three weeks treatment with intravenous ceftriaxone in
      patients with Lyme neuroborreliosis. The other purpose is to improve laboratory diagnostics
      of Lyme neuroborreliosis and further define the manifestations and epidemiology of the
      disease in Finland.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of the clinical condition during the study.</measure>
    <time_frame>12 months</time_frame>
    <description>The clinical condition of participants will be evaluated with visual analogue scale (from 0 to 10, 0=best) by the participants. The VAS scores are collected before the treatment with antibiotics, and 4 months and 12 months after the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The clinical condition evaluated by the participants after 12 months from the treatment</measure>
    <time_frame>12 months</time_frame>
    <description>The clinical condition is evaluated with VAS by the participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central spinal fluid (CSF) pleocytosis</measure>
    <time_frame>3 weeks</time_frame>
    <description>The decline in CSF leukocyte count between the patients in doxycycline and ceftriaxone groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF protein concentration</measure>
    <time_frame>3 weeks</time_frame>
    <description>The decline in CSF protein concentration between the patients in doxycycline and ceftriaxone groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF lactate level</measure>
    <time_frame>3 weeks</time_frame>
    <description>The decline in CSF lactate level between the patients in doxycycline and ceftriaxone groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF CXCL13 concentration</measure>
    <time_frame>3 weeks</time_frame>
    <description>The decline in CSF CXCL13 concentration wetween the patients in doxycycline and ceftriaxone groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Lyme Neuroborreliosis</condition>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of intravenous ceftriaxone (2 g/day), three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with oral doxycycline (200mg / day), four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline: 100mg tablet two times per day, four weeks</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>2 g intravenous once a day, three weeks</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for definite Lyme neuroborreliosis (Criteria 1-3 or 1 and 4 fulfilled):

          1. Neurological symptoms suggestive of LNB without other obvious reasons

          2. CSF pleocytosis (&gt;4 leukocytes per mikrol)

          3. Intrathecal production of B. burgdorferi specific antibodies

          4. Detection of B. burgdorferi DNA in central spinal fluid

        Inclusion Cirteria for possible LNB (criteria 1 and 2 or 3 fullfilled):

          1. Neurological symptoms suggestive of LNB wihtout other obvious reasons

          2. Production of B. burgdorferi spesific antibodies in serum

          3. Erythema migrans during the previous three months

        Exclusion Criteria:

          -  pregnancy and breastfeeding

          -  women planning to get pregnant in two months

          -  age under 18

          -  handicapped persons

          -  prisoners

          -  use of any antibiotics two weeks before study treatments begins

          -  allergy for tetracyclines or cephalosporins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jukka Hyt√∂nen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisa Kortela</last_name>
    <role>Principal Investigator</role>
    <affiliation>HYKS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mari Kanerva</last_name>
    <role>Principal Investigator</role>
    <affiliation>HYKS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Airas</last_name>
    <role>Principal Investigator</role>
    <affiliation>TYKS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2012</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Jarmo Oksi</investigator_full_name>
    <investigator_title>vs.prof</investigator_title>
  </responsible_party>
  <keyword>doxycycline</keyword>
  <keyword>ceftriaxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Neuroborreliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

